サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：血液・骨髄がん治療の世界市場 - 成長、将来展望、競合分析（2022年～2030年）
市場調査レポート
商品コード
1165315

血液・骨髄がん治療の世界市場 - 成長、将来展望、競合分析（2022年～2030年）

Blood and Bone Marrow Cancer Treatment Market - Growth, Future Prospects and Competitive Analysis, 2022 - 2030
出版日: | 発行: Acute Market Reports | ページ情報: 英文 119 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
血液・骨髄がん治療の世界市場 - 成長、将来展望、競合分析（2022年～2030年）
出版日: 2022年08月04日
発行: Acute Market Reports
ページ情報: 英文 119 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の血液・骨髄がん治療の市場規模は、2018年の388億米ドルから、2027年までに749億米ドルに達し、2019年から2027年の予測期間中にCAGRで7.7%の成長が予測されています。

当レポートでは、世界の血液・骨髄がん治療市場について調査し、市場動向、競合情報、セグメント分析、新興動向、技術分析、企業プロファイルなどの情報を提供しています。

目次

第1章 序文

  • レポートの説明
  • 市場セグメンテーション
  • 調査手法

第2章 エグゼクティブサマリー

  • 市場スナップショット：世界の血液・骨髄がん治療市場
  • 世界の血液・骨髄がん治療市場：適応症別（2021年）
  • 世界の血液・骨髄がん治療市場：治療別（2021年）
  • 世界の血液・骨髄がん治療市場：地域別（2021年）
  • COVID-19の影響
  • 魅力的な投資提案：地域別（2021年）
  • 競合分析
    • 主要な血液・骨髄がん治療市場ベンダーの市場ポジショニング
    • 血液・骨髄がん治療市場ベンダーが採用する戦略
    • 主要な業界戦略

第3章 血液・骨髄がん治療市場：ビジネスの見通しと市場力学

  • イントロダクション
  • 世界の血液・骨髄がん治療市場金額（2020年～2030年）
  • 市場力学
    • 市場促進要因
    • 市場抑制要因
    • 主な課題
    • 主な機会
  • 促進要因・抑制要因の影響分析
  • シーソー分析
  • ポーターのファイブフォースモデル
  • PESTEL分析

第4章 血液・骨髄がん治療市場：適応症別（2020年～2030年）

  • 市場概要
  • 成長と収益分析：2021年対2030年
  • 市場セグメンテーション
    • 多発性骨髄腫
    • 白血病
    • リンパ腫
    • その他

第5章 血液・骨髄がん治療市場：治療別（2020年～2030年）

  • 市場概要
  • 成長と収益分析：2021年対2030年
  • 市場セグメンテーション
    • 化学療法
    • 免疫療法
    • 幹細胞移植
    • 放射線治療
    • パイプライン分析

第6章 北米の血液・骨髄がん治療市場（2020年～2030年）

  • 市場概要
  • 血液・骨髄がん治療市場：適応症別（2020年～2030年）
  • 血液・骨髄がん治療市場：治療別（2020年～2030年）
  • 血液・骨髄がん治療市場：地域別（2020年～2030年）
    • 北米

第7章 英国・欧州連合の血液・骨髄がん治療市場（2020年～2030年）

  • 市場概要
  • 血液・骨髄がん治療市場：適応症別（2020年～2030年）
  • 血液・骨髄がん治療市場：治療別（2020年～2030年）
  • 血液・骨髄がん治療市場：地域別（2020年～2030年）
    • 英国・欧州連合

第8章 アジア太平洋の血液・骨髄がん治療市場（2020年～2030年）

  • 市場概要
  • 血液・骨髄がん治療市場：適応症別（2020年～2030年）
  • 血液・骨髄がん治療市場：治療別（2020年～2030年）
  • 血液・骨髄がん治療市場：地域別（2020年～2030年）
    • アジア太平洋

第9章 ラテンアメリカの血液・骨髄がん治療市場（2020年～2030年）

  • 市場概要
  • 血液・骨髄がん治療市場：適応症別（2020年～2030年）
  • 血液・骨髄がん治療市場：治療別（2020年～2030年）
  • 血液・骨髄がん治療市場：地域別（2020年～2030年）
    • ラテンアメリカ

第10章 中東・アフリカの血液・骨髄がん治療市場（2020年～2030年）

  • 市場概要
  • 血液・骨髄がん治療市場：適応症別（2020年～2030年）
  • 血液・骨髄がん治療市場：治療別（2020年～2030年）
  • 血液・骨髄がん治療市場：地域別（2020年～2030年）
    • 中東・アフリカ

第11章 企業プロファイル

  • AstraZeneca, Plc.
  • Celgene, Inc.
  • Bristol Myers Squibb & Company
  • Eli Lilly & Company
  • Johnson & Johnson Company
  • F.Hoffman La-Roche Ltd.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer, Inc.
  • Varian Medical Systems, Inc.
図表

List of Tables

  • TABLE 1 Global Blood and Bone Marrow Cancer Treatment Market By Indication, 2020-2030, USD (Million)
  • TABLE 2 Global Blood and Bone Marrow Cancer Treatment Market By Therapy, 2020-2030, USD (Million)
  • TABLE 3 Global Blood and Bone Marrow Cancer Treatment Market By Pipeline Analysis, 2020-2030, USD (Million)
  • TABLE 4 Global Blood and Bone Marrow Cancer Treatment Market By Phase III Drug, 2020-2030, USD (Million)
  • TABLE 5 North America Blood and Bone Marrow Cancer Treatment Market By Indication, 2020-2030, USD (Million)
  • TABLE 6 North America Blood and Bone Marrow Cancer Treatment Market By Therapy, 2020-2030, USD (Million)
  • TABLE 7 North America Blood and Bone Marrow Cancer Treatment Market By Pipeline Analysis, 2020-2030, USD (Million)
  • TABLE 8 North America Blood and Bone Marrow Cancer Treatment Market By Phase III Drug, 2020-2030, USD (Million)
  • TABLE 9 UK and European Union Blood and Bone Marrow Cancer Treatment Market By Indication, 2020-2030, USD (Million)
  • TABLE 10 UK and European Union Blood and Bone Marrow Cancer Treatment Market By Therapy, 2020-2030, USD (Million)
  • TABLE 11 UK and European Union Blood and Bone Marrow Cancer Treatment Market By Pipeline Analysis, 2020-2030, USD (Million)
  • TABLE 12 UK and European Union Blood and Bone Marrow Cancer Treatment Market By Phase III Drug, 2020-2030, USD (Million)
  • TABLE 13 Asia Pacific Blood and Bone Marrow Cancer Treatment Market By Indication, 2020-2030, USD (Million)
  • TABLE 14 Asia Pacific Blood and Bone Marrow Cancer Treatment Market By Therapy, 2020-2030, USD (Million)
  • TABLE 15 Asia Pacific Blood and Bone Marrow Cancer Treatment Market By Pipeline Analysis, 2020-2030, USD (Million)
  • TABLE 16 Asia Pacific Blood and Bone Marrow Cancer Treatment Market By Phase III Drug, 2020-2030, USD (Million)
  • TABLE 17 Latin America Blood and Bone Marrow Cancer Treatment Market By Indication, 2020-2030, USD (Million)
  • TABLE 18 Latin America Blood and Bone Marrow Cancer Treatment Market By Therapy, 2020-2030, USD (Million)
  • TABLE 19 Latin America Blood and Bone Marrow Cancer Treatment Market By Pipeline Analysis, 2020-2030, USD (Million)
  • TABLE 20 Latin America Blood and Bone Marrow Cancer Treatment Market By Phase III Drug, 2020-2030, USD (Million)
  • TABLE 21 Middle East and Africa Blood and Bone Marrow Cancer Treatment Market By Indication, 2020-2030, USD (Million)
  • TABLE 22 Middle East and Africa Blood and Bone Marrow Cancer Treatment Market By Therapy, 2020-2030, USD (Million)
  • TABLE 23 Middle East and Africa Blood and Bone Marrow Cancer Treatment Market By Pipeline Analysis, 2020-2030, USD (Million)
  • TABLE 24 Middle East and Africa Blood and Bone Marrow Cancer Treatment Market By Phase III Drug, 2020-2030, USD (Million)

List of Figures

  • FIG. 1 Global Blood and Bone Marrow Cancer Treatment Market: Market Coverage
  • FIG. 2 Research Methodology and Data Sources
  • FIG. 3 Market Size Estimation - Top Down & Bottom-Up Approach
  • FIG. 4 Global Blood and Bone Marrow Cancer Treatment Market: Quality Assurance
  • FIG. 5 Global Blood and Bone Marrow Cancer Treatment Market, By Indication, 2021
  • FIG. 6 Global Blood and Bone Marrow Cancer Treatment Market, By Therapy, 2021
  • FIG. 7 Global Blood and Bone Marrow Cancer Treatment Market, By Geography, 2021
  • FIG. 8 Global Blood and Bone Marrow Cancer Treatment Market, By Indication, 2021 Vs 2030, %
  • FIG. 9 Global Blood and Bone Marrow Cancer Treatment Market, By Therapy, 2021 Vs 2030, %
  • FIG. 10 U.S. Blood and Bone Marrow Cancer Treatment Market (US$ Million), 2020 - 2030
  • FIG. 11 Canada Blood and Bone Marrow Cancer Treatment Market (US$ Million), 2020 - 2030
  • FIG. 12 Rest of North America Blood and Bone Marrow Cancer Treatment Market (US$ Million), 2020 - 2030
  • FIG. 13 UK Blood and Bone Marrow Cancer Treatment Market (US$ Million), 2020 - 2030
  • FIG. 14 Germany Blood and Bone Marrow Cancer Treatment Market (US$ Million), 2020 - 2030
  • FIG. 15 Spain Blood and Bone Marrow Cancer Treatment Market (US$ Million), 2020 - 2030
  • FIG. 16 Italy Blood and Bone Marrow Cancer Treatment Market (US$ Million), 2020 - 2030
  • FIG. 17 France Blood and Bone Marrow Cancer Treatment Market (US$ Million), 2020 - 2030
  • FIG. 18 Rest of Europe Blood and Bone Marrow Cancer Treatment Market (US$ Million), 2020 - 2030
  • FIG. 19 China Blood and Bone Marrow Cancer Treatment Market (US$ Million), 2020 - 2030
  • FIG. 20 Japan Blood and Bone Marrow Cancer Treatment Market (US$ Million), 2020 - 2030
  • FIG. 21 India Blood and Bone Marrow Cancer Treatment Market (US$ Million), 2020 - 2030
  • FIG. 22 Australia Blood and Bone Marrow Cancer Treatment Market (US$ Million), 2020 - 2030
  • FIG. 23 South Korea Blood and Bone Marrow Cancer Treatment Market (US$ Million), 2020 - 2030
  • FIG. 24 Rest of Asia Blood and Bone Marrow Cancer Treatment Market (US$ Million), 2020 - 2030
  • FIG. 25 Brazil Blood and Bone Marrow Cancer Treatment Market (US$ Million), 2020 - 2030
  • FIG. 26 Mexico Blood and Bone Marrow Cancer Treatment Market (US$ Million), 2020 - 2030
  • FIG. 27 Rest of Latin America Blood and Bone Marrow Cancer Treatment Market (US$ Million), 2020 - 2030
  • FIG. 28 GCC Blood and Bone Marrow Cancer Treatment Market (US$ Million), 2020 - 2030
  • FIG. 29 Africa Blood and Bone Marrow Cancer Treatment Market (US$ Million), 2020 - 2030
  • FIG. 30 Rest of Middle East and Africa Blood and Bone Marrow Cancer Treatment Market (US$ Million), 2020 - 2030
目次
Product Code: 138867-08-22

Industry Outlook

The blood and bone marrow cancer treatment market is set to reach from US$ 38.8 Bn in 2018 to US$ 74.9 Bn by 2027 at a compound annual growth rate (CAGR) of 7.7% during the forecast period from 2019 to 2027. As per the research findings brought forward by Janssen Pharmaceutica N.V. approximately 900,000 people throughout the globe are diagnosed with blood cancer annually, it holds a share of 7% of all types of known cancer.

"Increasing prescription of immunosuppressive drugs for treating chronic infections and genetic mutation together are responsible for the growing incidence of lymphoma worldwide"

Lymphoma is leading the indication segment for blood and bone marrow cancer treatment market. Hodgkin lymphoma and Non-Hodgkin lymphoma are the 2 types prevalent worldwide. The important parameters responsible for its growing incidence throughout the globe are increasing prescription of immunosuppressant drugs for treating chronic infections and genetic mutations. Leukemia occurs when the DNA of immature white blood cells gets damaged due to exposure to ionizing radiation, hazardous chemicals, smoking, etc. The prevalence rate varies according to ethnicity with high occurrence in men in comparison to women population worldwide.

"Strong product pipeline will ensure rampant market growth for immunotherapy during the forecast period"

Chemotherapy is dominating the therapy segment for blood and bone marrow cancer treatment market. The primary factor responsible for its increasing prescription worldwide is the availability of its generic version at affordable cost, drastically reducing the healthcare burden on ailing patients. Oncologists frequently use them in combination therapy either with radiotherapy or immunotherapy to treat patients showing resistance to first-line drug therapy. Immunotherapy is set to register impressive growth in the near future on account of its promising product pipeline which will be commercially available during the forecast period.

"Rising prevalence of blood cancer and affordable reimbursement scenario for the medicines employed in its treatment together drive the market growth in North America"

North America with a market share of 34.6% is currently reigning the regional segment for blood and bone marrow cancer treatment market. The chief contributing factor for its market dominance is rising prevalence of blood cancer. According to the Leukemia and Lymphoma Society (CDC) facts and figures approximately after every 3 minutes 1 person in the U.S. is diagnosed with blood cancer. In 2019, in the United States, approximately 176,200 people are diagnosed with either leukemia, myeloma or lymphoma. Affordable reimbursement scenario for the medicines employed in its treatment is another important factor that contributes towards its regional market growth. Europe holds a share of 30.8% primarily due to the supportive regulatory framework provided by the European Medical Agency for the development and sale of medication for the treatment of blood cancer. Asia Pacific represents 18.4% market share on account of rising public health awareness related to blood cancer & its treatment and developing healthcare infrastructure.

Pharmaceutical companies spearheading the blood and bone marrow cancer treatment market are Bristol Myers Squibb & Company, AstraZeneca, Plc., Eli Lilly & Company, Johnson and Johnson Company, F.Hoffman La-Roche Ltd., Celgene, Inc., Merck & Co., Inc., Novartis AG, Varian Medical Systems, Inc. and Pfizer, Inc.

Historical & Forecast Period

This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Blood and Bone Marrow Cancer Treatment market are as follows:

Research and development budgets of manufacturers and government spending

Revenues of key companies in the market segment

Number of end users and consumption volume, price and value.

Geographical revenues generate by countries considered in the report:

Micro and macro environment factors that are currently influencing the Blood and Bone Marrow Cancer Treatment market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Market Segmentation

Indication

Multiple Myeloma

Leukemia

Lymphoma

Others

Therapy

Chemotherapy

Immunotherapy

Stem Cell Transplant

Radiotherapy

Pipeline Analysis

Phase III Drug

Eltrombopag

Avatrombopag

Hetrombopag

Omidubicel

Fedratinib

ATIR101

Pegylated Proline Interferon Alpha-2b

Tabular Representation of Phase II and I Pipeline Drugs

Region Segment (2020-2030; US$ Million)

North America

U.S.

Canada

Rest of North America

UK and European Union

UK

Germany

Spain

Italy

France

Rest of Europe

Asia Pacific

China

Japan

India

Australia

South Korea

Rest of Asia Pacific

Latin America

Brazil

Mexico

Rest of Latin America

Middle East and Africa

GCC

Africa

Rest of Middle East and Africa

Global Impact of COVID-19 Segment (2020-2021; US$ Million )

Pre COVID-19 situation

Post COVID-19 situation

Key questions answered in this report:

What are the key micro and macro environmental factors that are impacting the growth of Blood and Bone Marrow Cancer Treatment market?

What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?

Estimated forecast and market projections up to 2030.

Which segment accounts for the fastest CAGR during the forecast period?

Which market segment holds a larger market share and why?

Are low and middle-income economies investing in the Blood and Bone Marrow Cancer Treatment market?

Which is the largest regional market for Blood and Bone Marrow Cancer Treatment market?

What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?

Which are the key trends driving Blood and Bone Marrow Cancer Treatment market growth?

Who are the key competitors and what are their key strategies to enhance their market presence in the Blood and Bone Marrow Cancer Treatment market worldwide?

Table of Contents

1. Preface

  • 1.1. Report Description
    • 1.1.1. Purpose of the Report
    • 1.1.2. Target Audience
    • 1.1.3. Key Offerings
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
    • 1.3.1. Phase I - Secondary Research
    • 1.3.2. Phase II - Primary Research
    • 1.3.3. Phase III - Expert Panel Review
    • 1.3.4. Assumptions
    • 1.3.5. Approach Adopted

2. Executive Summary

  • 2.1. Market Snapshot: Global Blood and Bone Marrow Cancer Treatment Market
  • 2.2. Global Blood and Bone Marrow Cancer Treatment Market, By Indication, 2021 (US$ Million)
  • 2.3. Global Blood and Bone Marrow Cancer Treatment Market, By Therapy, 2021 (US$ Million)
  • 2.4. Global Blood and Bone Marrow Cancer Treatment Market, By Geography, 2021 (US$ Million)
  • 2.5. Impact of Covid 19
  • 2.6. Attractive Investment Proposition by Geography, 2021
  • 2.7. Competitive Analysis
    • 2.7.1. Market Positioning of Key Blood and Bone Marrow Cancer Treatment Market Vendors
    • 2.7.2. Strategies Adopted by Blood and Bone Marrow Cancer Treatment Market Vendors
    • 2.7.3. Key Industry Strategies

3. Blood and Bone Marrow Cancer Treatment Market: Business Outlook & Market Dynamics

  • 3.1. Introduction
  • 3.2. Global Blood and Bone Marrow Cancer Treatment Market Value, 2020 - 2030, (US$ Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers
    • 3.3.2. Market Restraints
    • 3.3.3. Key Challenges
    • 3.3.4. Key Opportunities
  • 3.4. Impact Analysis of Drivers and Restraints
  • 3.5. See-Saw Analysis
  • 3.6. Porter's Five Force Model
    • 3.6.1. Supplier Power
    • 3.6.2. Buyer Power
    • 3.6.3. Threat Of Substitutes
    • 3.6.4. Threat Of New Entrants
    • 3.6.5. Competitive Rivalry
  • 3.7. PESTEL Analysis
    • 3.7.1. Political Landscape
    • 3.7.2. Economic Landscape
    • 3.7.3. Technology Landscape
    • 3.7.4. Legal Landscape
    • 3.7.5. Social Landscape

4. Blood and Bone Marrow Cancer Treatment Market: By Indication, 2020-2030, USD (Million)

  • 4.1. Market Overview
  • 4.2. Growth & Revenue Analysis: 2021 Versus 2030
  • 4.3. Market Segmentation
    • 4.3.1. Multiple Myeloma
    • 4.3.2. Leukemia
    • 4.3.3. Lymphoma
    • 4.3.4. Others

5. Blood and Bone Marrow Cancer Treatment Market: By Therapy, 2020-2030, USD (Million)

  • 5.1. Market Overview
  • 5.2. Growth & Revenue Analysis: 2021 Versus 2030
  • 5.3. Market Segmentation
    • 5.3.1. Chemotherapy
    • 5.3.2. Immunotherapy
    • 5.3.3. Stem Cell Transplant
    • 5.3.4. Radiotherapy
    • 5.3.5. Pipeline Analysis
      • 5.3.5.1. Phase III Drug
        • 5.3.5.1.1. Eltrombopag
        • 5.3.5.1.2. Avatrombopag
        • 5.3.5.1.3. Hetrombopag
        • 5.3.5.1.4. Omidubicel
        • 5.3.5.1.5. Fedratinib
        • 5.3.5.1.6. ATIR101
        • 5.3.5.1.7. Pegylated Proline Interferon Alpha-2b
      • 5.3.5.2. Tabular Representation of Phase II and I Pipeline Drugs

6. North America Blood and Bone Marrow Cancer Treatment Market, 2020-2030, USD (Million)

  • 6.1. Market Overview
  • 6.2. Blood and Bone Marrow Cancer Treatment Market: By Indication, 2020-2030, USD (Million)
  • 6.3. Blood and Bone Marrow Cancer Treatment Market: By Therapy, 2020-2030, USD (Million)
  • 6.4.Blood and Bone Marrow Cancer Treatment Market: By Region, 2020-2030, USD (Million)
    • 6.4.1.North America
      • 6.4.1.1. U.S.
      • 6.4.1.2. Canada
      • 6.4.1.3. Rest of North America

7. UK and European Union Blood and Bone Marrow Cancer Treatment Market, 2020-2030, USD (Million)

  • 7.1. Market Overview
  • 7.2. Blood and Bone Marrow Cancer Treatment Market: By Indication, 2020-2030, USD (Million)
  • 7.3. Blood and Bone Marrow Cancer Treatment Market: By Therapy, 2020-2030, USD (Million)
  • 7.4.Blood and Bone Marrow Cancer Treatment Market: By Region, 2020-2030, USD (Million)
    • 7.4.1.UK and European Union
      • 7.4.1.1. UK
      • 7.4.1.2. Germany
      • 7.4.1.3. Spain
      • 7.4.1.4. Italy
      • 7.4.1.5. France
      • 7.4.1.6. Rest of Europe

8. Asia Pacific Blood and Bone Marrow Cancer Treatment Market, 2020-2030, USD (Million)

  • 8.1. Market Overview
  • 8.2. Blood and Bone Marrow Cancer Treatment Market: By Indication, 2020-2030, USD (Million)
  • 8.3. Blood and Bone Marrow Cancer Treatment Market: By Therapy, 2020-2030, USD (Million)
  • 8.4.Blood and Bone Marrow Cancer Treatment Market: By Region, 2020-2030, USD (Million)
    • 8.4.1.Asia Pacific
      • 8.4.1.1. China
      • 8.4.1.2. Japan
      • 8.4.1.3. India
      • 8.4.1.4. Australia
      • 8.4.1.5. South Korea
      • 8.4.1.6. Rest of Asia Pacific

9. Latin America Blood and Bone Marrow Cancer Treatment Market, 2020-2030, USD (Million)

  • 9.1. Market Overview
  • 9.2. Blood and Bone Marrow Cancer Treatment Market: By Indication, 2020-2030, USD (Million)
  • 9.3. Blood and Bone Marrow Cancer Treatment Market: By Therapy, 2020-2030, USD (Million)
  • 9.4.Blood and Bone Marrow Cancer Treatment Market: By Region, 2020-2030, USD (Million)
    • 9.4.1.Latin America
      • 9.4.1.1. Brazil
      • 9.4.1.2. Mexico
      • 9.4.1.3. Rest of Latin America

10. Middle East and Africa Blood and Bone Marrow Cancer Treatment Market, 2020-2030, USD (Million)

  • 10.1. Market Overview
  • 10.2. Blood and Bone Marrow Cancer Treatment Market: By Indication, 2020-2030, USD (Million)
  • 10.3. Blood and Bone Marrow Cancer Treatment Market: By Therapy, 2020-2030, USD (Million)
  • 10.4.Blood and Bone Marrow Cancer Treatment Market: By Region, 2020-2030, USD (Million)
    • 10.4.1.Middle East and Africa
      • 10.4.1.1. GCC
      • 10.4.1.2. Africa
      • 10.4.1.3. Rest of Middle East and Africa

11. Company Profile

  • 11.1. AstraZeneca, Plc.
    • 11.1.1. Company Overview
    • 11.1.2. Financial Performance
    • 11.1.3. Product Portfolio
    • 11.1.4. Strategic Initiatives
  • 11.2. Celgene, Inc.
    • 11.2.1. Company Overview
    • 11.2.2. Financial Performance
    • 11.2.3. Product Portfolio
    • 11.2.4. Strategic Initiatives
  • 11.3. Bristol Myers Squibb & Company
    • 11.3.1. Company Overview
    • 11.3.2. Financial Performance
    • 11.3.3. Product Portfolio
    • 11.3.4. Strategic Initiatives
  • 11.4. Eli Lilly & Company
    • 11.4.1. Company Overview
    • 11.4.2. Financial Performance
    • 11.4.3. Product Portfolio
    • 11.4.4. Strategic Initiatives
  • 11.5. Johnson & Johnson Company
    • 11.5.1. Company Overview
    • 11.5.2. Financial Performance
    • 11.5.3. Product Portfolio
    • 11.5.4. Strategic Initiatives
  • 11.6. F.Hoffman La-Roche Ltd.
    • 11.6.1. Company Overview
    • 11.6.2. Financial Performance
    • 11.6.3. Product Portfolio
    • 11.6.4. Strategic Initiatives
  • 11.7. Merck & Co., Inc.
    • 11.7.1. Company Overview
    • 11.7.2. Financial Performance
    • 11.7.3. Product Portfolio
    • 11.7.4. Strategic Initiatives
  • 11.8. Novartis AG
    • 11.8.1. Company Overview
    • 11.8.2. Financial Performance
    • 11.8.3. Product Portfolio
    • 11.8.4. Strategic Initiatives
  • 11.9. Pfizer, Inc.
    • 11.9.1. Company Overview
    • 11.9.2. Financial Performance
    • 11.9.3. Product Portfolio
    • 11.9.4. Strategic Initiatives
  • 11.10. Varian Medical Systems, Inc.
    • 11.10.1. Company Overview
    • 11.10.2. Financial Performance
    • 11.10.3. Product Portfolio
    • 11.10.4. Strategic Initiatives